SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591) announced that its Efsubaglutide alfa manufacturing facility in Suzhou has passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) standards. The company has received the GMP certificate from ANVISA.
This recognition confirms that the manufacturing site meets international PIC/S GMP standards, supporting registration and market access for Efsubaglutide alfa in Brazil and other emerging markets. Brazil serves as a strategic hub for expansion into South America and other PIC/S member countries.
Brazil has a high diabetes burden, with about 16.6 million adults living with diabetes, according to the International Diabetes Federation. The country's pharmaceutical market reached US$35.6 billion in 2023, making it a key focus for Innogen's overseas commercialization.
Efsubaglutide alfa is an innovative, human-derived, ultra-long-acting GLP-1 receptor agonist developed by Innogen. It is approved in Mainland China and Macau for type 2 diabetes and included in China's National Reimbursement Drug List. Clinical studies showed significant HbA1c reduction and weight loss benefits.
Professor Wang Qinghua, Founder, Chairman, and CEO, said the certificate marks a milestone in global quality systems and will accelerate registration and launch across PIC/S-aligned markets. The company continues to develop Efsubaglutide alfa for diabetes and obesity globally.
Source: prnewswire.com
